PCI Pharma Services Establishes New Center of Excellence Facility in the Midwest to Increase Biologics Leadership
PCI Pharma Services (PCI), a global leader in contract development and manufacturing, has announced a new 200,000-square-foot facility in Rockford, Illinois. This expansion aims to boost PCI’s capacity in assembling injectable drug-device combination products for biologics and small molecules. Building on the success of their Philadelphia Biotech Center of Excellence, the Rockford facility will feature over 20 customer suites equipped with versatile machines for assembling and packaging vials, pre-filled syringes, auto-injectors, and pen-cartridge combinations. These machines are essential for producing GLP-1 drugs for diabetes and obesity, as well as treatments for oncology and autoimmune diseases.
The Rockford site will include extensive product testing capabilities, advanced top-load cartoning technology, and leading-edge injector and pen assembly equipment. Additional features include on-site cold storage, high-speed vial labeling, multiformat autoinjector assembly and packaging, serialization, testing, and drug product release.
Salim Haffar, CEO of PCI Pharma Services, emphasized the investment’s impact on patient care, highlighting the critical need for injectable drug-delivery device expertise. The $50 million Rockford facility will enhance PCI’s specialty drug services in the Midwest, complementing their sterile fill-finish capabilities in Madison, Wisconsin, and expanding PCI’s U.S. presence from its Northeast base. This new site is expected to create 250 jobs within two years and become fully operational by summer 2024.
Gil Valadez, Senior Vice President of Commercial Packaging Technology at PCI, noted that the facility will enable PCI to support clients focused on injectable drug products, allowing them to concentrate on delivering high-quality medicines to patients. This expansion aligns with PCI’s mission to manage the technical aspects of drug manufacturing and delivery, ensuring that life-changing treatments reach those in need.